Symbol not found

NASDAQ:REGN   00:00AM GMT
0.00
0.00 (0.00%)
Products

Eylea (Aflibercept) Injection Sbla For Every 16-Week Dosing Regimen In Patients With Diabetic Retinopathy Accepted For FDA Review

Published: 06/29/2022 11:37 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Eylea® (aflibercept) Injection Sbla for Every 16-week Dosing Regimen in Patients With Diabetic Retinopathy Accepted for FDA Review.
Regeneron Pharmaceuticals Inc - Target Action Date for FDA Decision is February 28, 2023.
Regeneron Pharmaceuticals Inc - Potential Use of 16-week Dosing Regimen for Eylea in Dr Has Not Been Fully Evaluated by Any Regulatory Authority.